Post-earnings recap
Reported
Thu, Oct 30, 2025
EPS actual
$1.67
EPS est.
$1.03
EPS surprise
+62.14%
1-day move
-31.01%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Despite beating EPS expectations significantly, Apellis Pharmaceutical's stock dropped by over 31% in reaction to the earnings report. The lack of revenue data and forward guidance contributed to investor uncertainty. Management's defensive tone suggests that the company is facing challenges that could impact future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.67 | N/A | +62.14% |
| Revenue | N/A | N/A | N/A |
Management expressed concerns about market conditions impacting future performance. They did not provide specific guidance for the upcoming quarters.
Management highlighted ongoing challenges in the market.
They emphasized the need for strategic adjustments moving forward.